Anti-tumor effect of the insulin-like growth factor-1 receptor (IGF-1R) on human pancreatic cancer cells in both in vitro and in vivo studies

• FUNAKOSHI Akihiro

  International University of Health and Welfare Department of Pancreatology, Fukuoka Sanno Hospital

• KAWANAMI Takako

  Research Institute, National Kyushu Cancer Center

• TAKIGUCHI Soichi

  Research Institute, National Kyushu Cancer Center

Bibliographic Information

Other Title

• 膵癌由来細胞に対するヒト抗インスリン様成長因子１受容体抗体の腫瘍抑制効果

Abstract

The insulin-like growth factor-1 receptor(IGF-1R) signaling pathway is frequently deregulated in human tumors and is a target of interest for anti-tumor therapy. Roche R1507 is a fully humanized IGF-1R monoclonal antibody. We evaluated the effects of R1507 on the growth of several pancreatic tumor cell lines in vitro and in vivo. We found pancreatic tumor cell lines moderately expressed IGF-1R by qRT-PCR. The growth inhibitory effect of R1507 against several pancreatic cell lines was determined by IC₅₀ value. Combined R1507 and Gemcitabine or 5-FU has superior additive effect to gemcitabine or 5-FU alone. R1507 showed significant survival in the nude mice intraperitoneal dissemination model with Suit-2 cells. In conclusion, R1507, used alone or combined with gemcitabine is a promising anticancer drug on human pancreatic cancer cells.<br>

Journal

• Suizo

  Suizo 26 (5), 575-582, 2011

  Japan Pancreas Society

Keywords

• IGF-1
• Gemcitabine
• 5-FU

Details

• CRID: 1390282679616041728
• NII Article ID: 130004495973
• NII Article ID: 10030473847
• NII Book ID: AN10043798
• DOI: 10.2958/suizo.26.575
• ISSN: 18812805
• ISSN: 09130071
• Web Site: https://search.jamas.or.jp/link/ui/2012042898
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed